In March 2020 the IASC Reference Group on Mental Health and Psychosocial Support uniting 57 humanitarian organizations as member issued the Interim Briefing Note Addressing Mental Health and Psychosocial Aspects of COVID-19 Outbreak. This document has proven to be very useful in the response and has... till now been translated in 24 languages. It covers a set of recommended activities as well as messages for different target groups.
The current document is an annex to the Interim Briefing Note and is meant to support the MHPSS operational response within the various sectors of humanitarian work. Approaches and interventions to MHPSS are not confined to one sector, but need to be integrated within many existing sectors and clusters.This document contains a wealth of operational information and practical approaches that can be used for humanitarian programming in health, SGBV, community-based protection, nutrition, camp management and camp coordination.
more
Настоящие руководящие принципы предназначены для специалистов, имеющих дело с теми потребителями наркотиков, которые применяют наиболее проблемные модели потре...ления и подвергаются самому высокому риску ВИЧ-инфекции и туберкулеза, особенно это касается лиц, употребляющих инъекционные наркотики.
more
Этот документ содержит техническое руководство для стран по мониторингу усилий, направленных на
профилактику и лечение ВИЧ-инфекции среди людей, употребляющих и...ъекционные наркотики (ЛУИН),
и определению амбициозных, но достижимых задач национального уровня для расширения всеобщего
доступа к услугам.
more
March 28, 2017https://doi.org/10.1371/journal.pmed.1002274
PLoS Med 14(3): e1002274. https://doi.org/10.1371/journal.pmed.1002274
The ICAT is a simple and practical approach for assessing the adequacy of existing infection prevention and control practices and provides specific recommendations for improving practices and monitoring their effectiveness over time
This document is a guide for national authorities who are responsible for managing public health responses to COVID-19
Q 2: How long should treatment with antidepressants continue in adults with depressive episode/disorder?
A review of prospects for existing antibiotics ad new therapeutics
Q9: Antidepressant medicines in individuals with a depressive episode in bipolar disorder1Q9: In individuals presenting with a depressive episode in bipolar disorder, are antidepressant medicines effective and safe?
Q10: In individuals with psychotic disorders (including schizophrenia) and bipolar disorders are psychoeducation, family interventions and cognitive-behavioural therapy feasible and effective?
DHS Working Papers No. 110 | Zimbabwe Working Papers No. 11
Hand Hygiene: Why, How, & When?
Key populations brief
Accessed November 2017
The latest update (28 January 2021) includes the following addition and revision:
biosafety aspects for working with antigen-detecting rapid diagnostic test;
handling new variants of SARS-CoV-2 in the laboratory;
updated assay decontamination before disposal;
personal protectiv...e equipment (PPE) for specimen collection;
addressing chemical hazards and their safe disposal; and
the fourth edition of the WHO Laboratory Biosafety Manual (LBM4) is now available and the terminology in this guidance was aligned with the LBM4.
more
WHO-AIMS REPORT ON MENTAL HEALTH SYSTEM IN NEPAL
A report of the assessment of the mental health system in Nepal using the World Health Organization - Assessment Instrument for
Mental Health Systems (WHO-AIMS).
Kathmandu, Nepal
The international community sits at the tipping pointof a post-‐antibiotic era, where common bacterial infections are no longer treatable with the antibiotic armamentarium that exists. In South Africa, t...he identification of the first case of pan-‐resistant Klebsiella pneumoniae(Brink et al, J Clin Microbiol. 2013;51(1):369-‐72) marks a watershed moment and highlights ourtip of the antibiotic resistance ‘iceberg’ in this country. Multi-‐drug resistant (MDR)-‐bacterial infections, predominantly in Gram-‐negative bacteria such as Klebsiella pneumoniae, Escherichia coli, Pseudomonas aeruginosaand Acinetobacter baumanniiare now commonplace in South African hospitals. Whilst a number of expensive new antibiotics for Gram-‐positive bacterial infections have been manufactured recently (some of which are licenced for usein South Africa), no new antibiotics active against Gram-‐negative infections are expected in the next 10-‐15years. Hence what we have now, needs conserving
more